These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. What price pain relief? Hochman JS; Shah NR Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335 [No Abstract] [Full Text] [Related]
9. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Chan FK; Abraham NS; Scheiman JM; Laine L; Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980 [TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Salpeter SR; Gregor P; Ormiston TM; Whitlock R; Raina P; Thabane L; Topol EJ Am J Med; 2006 Jul; 119(7):552-9. PubMed ID: 16828623 [TBL] [Abstract][Full Text] [Related]
11. [Non steroidal anti-inflammatory drugs (NSAIDs) - balancing gastrointestinal complications and the cardiovascular risk]. Kandulski A; Venerito M; Malfertheiner P Dtsch Med Wochenschr; 2009 Aug; 134(33):1635-40; quiz 1641-4. PubMed ID: 19650027 [TBL] [Abstract][Full Text] [Related]
12. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Messerli FH; Sichrovsky T Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380 [No Abstract] [Full Text] [Related]
13. The practice implications of cardiovascular risks in NSAIDs. Hainsworth T Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838 [TBL] [Abstract][Full Text] [Related]
15. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Bollini P; García Rodríguez LA; Pérez Gutthann S; Walker AM Arch Intern Med; 1992 Jun; 152(6):1289-95. PubMed ID: 1534651 [TBL] [Abstract][Full Text] [Related]
16. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. Hinz B; Renner B; Brune K Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610 [TBL] [Abstract][Full Text] [Related]
17. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Price-Forbes AN; Callaghan R; Allen ME; Rowe IF Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035 [TBL] [Abstract][Full Text] [Related]
18. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Hermann M; Ruschitzka F Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448 [TBL] [Abstract][Full Text] [Related]
20. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Hermann M; Ruschitzka F Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]